Free Trial
NASDAQ:CGON

CG Oncology Q2 2025 Earnings Report

CG Oncology logo
$24.85 +0.50 (+2.05%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$24.84 -0.02 (-0.06%)
As of 08/8/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CG Oncology EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.49
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

CG Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.11 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CG Oncology Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 8, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

CG Oncology's Q3 2025 earnings is scheduled for Thursday, August 14, 2025

CG Oncology Earnings Headlines

CG Oncology’s Q2 2025: Clinical Advances and Legal Wins
Amazon’s big Bitcoin embarrassment
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.
CG Oncology (CGON) to Release Quarterly Earnings on Thursday
See More CG Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CG Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CG Oncology and other key companies, straight to your email.

About CG Oncology

CG Oncology (NASDAQ:CGON), an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

View CG Oncology Profile

More Earnings Resources from MarketBeat